Ensysce Biosciences (ENSC) to Release Earnings on Friday

Ensysce Biosciences (NASDAQ:ENSC) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Friday, May 9th. Analysts expect Ensysce Biosciences to post earnings of ($3.02) per share for the quarter.

Ensysce Biosciences (NASDAQ:ENSC) last issued its quarterly earnings results on Monday, March 10th. The company reported ($2.90) earnings per share for the quarter, missing the consensus estimate of ($2.74) by ($0.16). Ensysce Biosciences had a negative net margin of 179.26% and a negative return on equity of 292.81%. The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $0.25 million. On average, analysts expect Ensysce Biosciences to post $-8 EPS for the current fiscal year and $-13 EPS for the next fiscal year.

Ensysce Biosciences Price Performance

Shares of NASDAQ:ENSC opened at $2.97 on Friday. Ensysce Biosciences has a 1-year low of $1.62 and a 1-year high of $14.67. The business has a fifty day moving average price of $3.30 and a 200-day moving average price of $5.95. The company has a market capitalization of $4.89 million, a PE ratio of -0.11 and a beta of 1.06.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.